You are here:

perampanel (Fycompa®)

Advice

in the absence of a submission from the holder of the marketing authorisation:

perampanel (Fycompa®) is not recommended for use within NHS Scotland.

Indication under review: Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: perampanel (Fycompa®)
SMC Drug ID: 1200/16
Manufacturer: Eisai Ltd
Indication: adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 10 October 2016

Back